Novel Isoform of KCNH2 for the Treatment of Schizophrenia

Novel Isoform of KCNH2 for the Treatment of Schizophrenia

Researchers at the NIH report the discovery and characterization of a novel isoform of the voltage-gated potassium channel KCNH2. This novel isoform is shown to control neurological firing and has implication as a genetic risk factor for schizophrenia. It is highly expressed in the hippocampus of schizophrenic patients and also in normal individuals who carry risk-associated alleles of KCNH2. This novel isoform may be a suitable target for drug development as is it minimally expressed in the heart with the potential to exert less adverse cardiovascular side-effects, which is often a consequence of currently available antipsychotic drugs.
Abstract: 
Researchers at the NIH report the discovery and characterization of a novel isoform of the voltage-gated potassium channel KCNH2. This novel isoform is shown to control neurological firing and has implication as a genetic risk factor for schizophrenia. It is highly expressed in the hippocampus of schizophrenic patients and also in normal individuals who carry risk-associated alleles of KCNH2. This novel isoform may be a suitable target for drug development as is it minimally expressed in the heart with the potential to exert less adverse cardiovascular side-effects, which is often a consequence of currently available antipsychotic drugs. Available for licensing and commercial development are nucleic acids, polypeptides and antibodies specific for this novel isoform, as well as methods of screening for therapeutic agents and predicting susceptibility to schizophrenia.
applications: 
Inventors: 

Bai Lu (NIMH)

Joel Kleinman (NIMH)

Stephen Huffaker (NIMH)

Daniel Weinberger (NIMH)

Patent Number: 
PCT/US13/22878 US Application No. 12/593,159 US Ap
Internal Laboratory Ref #: 
E-245-2006/0 Updated: Aug 17, 2016
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin